RBC Capital reiterates Outperform on Edwards Lifesciences
RBC Capital analyst Shagun Singh reiterated an Outperform rating on Edwards Lifesciences with a maintained price target of $100.
*this image is generated using AI for illustrative purposes only.
RBC Capital analyst Shagun Singh has reiterated an Outperform rating for Edwards Lifesciences, maintaining a price target of $100. The rating affirmation underscores confidence in the company's market position.
Analyst Rating and Price Target
The research note highlights the firm's continued positive outlook on Edwards Lifesciences. The $100 price target remains unchanged, suggesting potential upside from current levels.
| Metric | Value |
|---|---|
| Rating | Outperform |
| Price Target | $100 |
What specific catalysts does RBC Capital anticipate will drive Edwards Lifesciences' stock toward the $100 price target?
How might upcoming clinical trial results or product launches impact Edwards Lifesciences' market position in the near term?
What competitive pressures could Edwards Lifesciences face in its core markets, and how might these affect its growth trajectory?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
